Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

Smith & Nephew plc

SNN
Healthcare · Medical Devices

Smith & Nephew plc's earnings have outrun its stock. EPS grew +52.3% in a year against a −24.6% price move.

The sharpest disagreement: annual EPS moved +52.3% against a −24.6% price move — the market has not yet caught up with the delivery.

The price is in a downtrend (4 weeks in). Underneath, the last four quarters read improving — profit +3.4% year on year, and 222% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Improving
fundamental trajectory, 12 quarters
Price
$27.8
−24.6% 1Y
P/E
18.6×
of its own 9-year range
Revenue (Jun 26)
$3.1 B
+4.7% YoY
Profit (Jun 26)
$0.3 B
+3.4% YoY
Operating margin
14.5%
flat YoY
ROE
12%
FY25
ROIC
8.7%
vs WACC 6.7% → +2.0 pp
Cash conversion
222%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Smith & Nephew plc trades at $27.8, in a downtrend and 4 weeks into that stage. That is −12.7% against its own 200-day average. It sits at 3% of a 52-week range of $28 to $37. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (22 weeks and counting).

Today the stock is in a downtrend — week 4 of stage 4. At $27.8 it trades −12.7% versus its 200-day average and sits at 3% of its 52-week range ($28–$37).

Sep 26: $27.8 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−12.7% versus the 200-day line, week 4 of stage 4
Price50-day avg200-day avg
S1S3S1S3S2S1$39.4$34.6$29.9$25.1$20.3$$28$32Sep 23Jun 24Mar 25Dec 25Sep 26
S1S3S1S3S2S1$39.4$34.6$29.9$25.1$20.3$$28$32Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (533 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Sep 26

Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved −19% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (22 weeks and counting; last ahead the week of 2026-04-17) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Smith & Nephew plc trades at 18.6× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 18.6× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 18.6× vs a null× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 8.7-year window; loss-period spikes above 25× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
against too little history to rank
P/EEPS (TTM) (quarterly)
26.5×$3.921.8×$2.917.2×$1.912.5×$1.07.8×$0.0×$10.75×$3Jan 18Feb 20May 22Jul 24Sep 26
26.5×$3.921.8×$2.917.2×$1.912.5×$1.07.8×$0.0×$10.75×$3Jan 18May 22Sep 26
P/E
18.6×
too little history to rank
PEG
1.96
derived from 3-year earnings growth

Why the multiple sits where it does: over the past year annual EPS moved +52.3% against a −24.6% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −5.5%/yr price move, ~+3.7%/yr came from earnings growth and ~−9.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Improving

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Smith & Nephew plc reads as improving on its fundamental arc. Improving — profit growth bottomed 4 quarters ago at −49.5% and has held its recovery at +115.4%, ROCE lifting at 17.7%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +6.0% in FY25, profit +53.7% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
7.0%67%5.1%33%3.3%0.0%1.4%−33%−0.5%−67%%%6%53.7%FY21FY23FY25
7.0%67%5.1%33%3.3%0.0%1.4%−33%−0.5%−67%%%6%53.7%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit accelerating
RevenueProfitEPS
13%129%8.5%81%4.4%33%0.3%−16%−3.7%−64%%%11.4%115.4%115.9%Dec 20Jul 23Jun 26
13%129%8.5%81%4.4%33%0.3%−16%−3.7%−64%%%11.4%115.4%115.9%Dec 20Jul 23Jun 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
19%15%11%6.6%2.6%%17.7%Dec 20Dec 21Jul 23Dec 24Jun 26
19%15%11%6.6%2.6%%17.7%Dec 20Jul 23Jun 26
Revenue growth
Steady high
latest +11.4% · span −2.6% to +11.4%
Profit growth
Flat
latest +115.4% · span −50.5% to +115.4%
EPS growth
Flat
latest +115.9% · span −50.0% to +115.9%
ROCE
Rising
latest 17.7% · span 3.7%–17.7%

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+6.0%+5.7%
Profit+53.7%+42.0%
EPS+52.3%+41.1%
Stock price−24.6%+1.9%−5.5%−1.6%
Revenue YoY (Jun 26)
+4.7%
latest quarter vs a year ago
Profit YoY (Jun 26)
+3.4%
latest quarter vs a year ago
Revenue 10y
4.3%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

44.5/100 — rank 30 of 30 in Medical Devices · 44% evidence confidence · provisional, ranked below fully-evidenced peers

Smith & Nephew plc scores 44.5 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 30. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 17.6 + 12.9 + 11 + 3 = 44.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Smith & Nephew plc reported $3.1 B of revenue in the Jun 26 quarter, +4.7% year on year. That is the 8th straight quarter of year-on-year growth. Over 4 years it has compounded at 4.3% a year. The last full year, FY25, came in at $6.2 B. The last four reported quarters add to $12.2 B.

FY25 revenue came in at $6.2 B (+6.0% on the year), capping 4 years at 4.3% compound. The latest quarter (Jun 26) printed $3.1 B, +4.7% year on year — the 8th consecutive quarter of year-over-year growth.

FY25 revenue $6.2 B (+6.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
4.3% a year over 4 years
RevenueYoY growth
6.77.0%5.05.1%3.33.3%1.71.4%0.0−0.5%$ B%$6B6%FY21FY23FY25
6.77.0%5.05.1%3.33.3%1.71.4%0.0−0.5%$ B%$6B6%FY21FY23FY25
Jun 26: $3.1 B (+4.7% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
8th straight quarter of growth
Revenue (quarterly)YoY growth
3.530%2.621%1.711%0.91.9%0.0−7.5%$ B%$3B4.7%Dec 20Jul 23Jun 26
3.530%2.621%1.711%0.91.9%0.0−7.5%$ B%$3B4.7%Dec 20Jul 23Jun 26

Pace check: the last four quarters averaged +5.7% growth against the decade's 4.3% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +11.4% over the last 4 quarters against +8.9%/yr over the last 8 — stabilising; TTM profit +115.4% vs +3.3%/yr — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Smith & Nephew plc's operating margin is 14.5% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +2.8 percentage points.

The latest quarter's operating margin is 14.5%, +0.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 7.6%–12.8%, and FY25's 12.8% is the top of that band — a record year.

Why the margin moved: operating margin went +2.8 pp year on year while gross margin went +1.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

FY25: 12.8% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
the widest a 7.6–12.8% band over 5 years
operating marginYoY change (pp)
13%4.3%12%2.4%10%0.5%8.7%−1.3%7.2%−3.2%%%12.8%1.4%FY21FY23FY25
13%4.3%12%2.4%10%0.5%8.7%−1.3%7.2%−3.2%%%12.8%1.4%FY21FY23FY25
Jun 26: 14.5% operating margin (+0.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
15%11%13%6.5%9.9%2.2%7.2%−2.2%4.6%−6.6%%%14.5%0%Dec 20Jul 23Jun 26
15%11%13%6.5%9.9%2.2%7.2%−2.2%4.6%−6.6%%%14.5%0%Dec 20Jul 23Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Smith & Nephew plc earned $0.3 B of net profit in the Jun 26 quarter, +3.4% year on year. It is the 6th consecutive quarter of growth. Full-year FY25 profit was $0.6 B. The 4-year compound rate is 4.9%. That is 9.7% of the quarter's revenue. The same quarter a year earlier earned $0.2 B.

Jun 26 profit was $0.3 B, +3.4% year on year — the 6th consecutive quarter of growth. On the full year, FY25 printed $0.6 B (+53.7%), and the 4-year compound rate is 4.9%.

FY25 profit $0.6 B (+53.7% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
4.9% a year over 4 years
Net profitYoY growth
0.767%0.533%0.30.0%0.2−33%0.0−67%$ B%$1B53.7%FY21FY23FY25
0.767%0.533%0.30.0%0.2−33%0.0−67%$ B%$1B53.7%FY21FY23FY25
Jun 26: $0.3 B (+3.4% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
6th straight quarter of growth
Net profit (quarterly)YoY growth
0.4139%0.379%0.219%0.1−41%0.0−101%$ B%$0B3.4%Dec 20Jul 23Jun 26
0.4139%0.379%0.219%0.1−41%0.0−101%$ B%$0B3.4%Dec 20Jul 23Jun 26

Why profit moved: revenue contributed +4.7% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +57.2% vs revenue +5.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 222% of Smith & Nephew plc's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $1.3 B of operating cash against $0.6 B of profit. After $0.4 B of capital spending, $0.8 B was left as free cash.

FY25: operating cash of $1.3 B against reported profit of $0.6 B, leaving free cash of $0.8 B after $0.4 B of capital spending. Across the last 3 fiscal years the conversion rate is 222% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $1.3 B vs profit $0.6 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
222% of 3-year profit arrived as cash
Operating cashNet profitFree cash
1.41.00.70.30.0$ B$1B$1B$1BFY21FY23FY25
1.41.00.70.30.0$ B$1B$1B$1BFY21FY23FY25
Jun 26: operating cash $0.5 B = 150% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
1.0582%0.7443%0.5305%0.2166%0.027%$ B%$1B150%Dec 20Jul 23Jun 26
1.0582%0.7443%0.5305%0.2166%0.027%$ B%$1B150%Dec 20Jul 23Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Smith & Nephew plc does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $1.0 B over the last 3 years. Averaged over those years that is 5.4% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $1.0 B over the last 3 fiscal years.

FY25: capex $0.4 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.50.30.20.10.0$ B$0BFY21FY23FY25
0.50.30.20.10.0$ B$0BFY21FY23FY25
Jun 26: capex $0.2 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)
0.310.230.160.080.00$ B$0BDec 20Jul 23Jun 26
0.310.230.160.080.00$ B$0BDec 20Jul 23Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Smith & Nephew plc earns a ROE of 12% in FY25. That is up from a trough of 5% in FY23. Return on invested capital clears the cost of that capital by +2.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 10.2% net margin on 0.59× asset turns.

FY25 ROE is 12%, recovered from a FY23 trough of 5% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 10.2% net margin × 0.59× asset turns × 1.98× balance-sheet leverage ≈ 11.9% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 8.7% − 6.7% = a +2.0 pp spread. The 6.7% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROE 12% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 6.7% cost of capital used on this page.
the climb back from FY23's 5%
ROEROIC (annual)WACC
202%149%96%43%−9.6%%11.9%8%FY21FY23FY25
202%149%96%43%−9.6%%11.9%8%FY21FY23FY25
Jun 26: ROIC 7.6% (TTM) vs WACC 6.7% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
31%25%18%11%4.6%%7.6%11.8%Sep 23Dec 24Jun 26
31%25%18%11%4.6%%7.6%11.8%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

Smith & Nephew plc pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Smith & Nephew plc does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Debt-to-equity is 0.73 at the latest reading — modestly levered; a full borrowings history is not in our numbers.

We hold only the latest reading here: a debt-to-equity of 0.73 — a modest level of leverage behind the returns above. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.

13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

No ownership or positioning reading is held for Smith & Nephew plc, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 4.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

We hold no ownership or positioning reading for this stock, so this section says that plainly.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Smith & Nephew plc: the Z-score reads 3.26. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 3.26 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 3.26.

15 · Related companies · Medical Devices
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1DexCom, Inc.DXCM 75.7/100Favorable setup85% evidence BREAKING OUT 27.8/35 Revenue 15.5% · PAT 74.8% · OPM change 5.9 pp 95% evidence 16.5/25 ROCE 7.8% · OPM 24.3% 76% evidence 14.2/20 P/E 26.6× · PEG 0.68 65% evidence 17.2/20 RS sector 13.1% · RS bench 16.5% · 1Y 29.5%11 of 12 weeks ahead 100% evidence
Exact sum: 27.8 + 16.5 + 14.2 + 17.2 = 75.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Boston Scientific CorporationBSX 60.7/100Mixed-positive evidence85% evidence BASING 24.6/35 Revenue 13.5% · PAT 46.9% · OPM change 5.4 pp 95% evidence 15.2/25 ROCE 3.1% · OPM 21.6% 76% evidence 16.2/20 P/E 17.3× · PEG 0.37 65% evidence 4.7/20 RS sector -44.2% · RS bench -42.8% · 1Y -55.1%0 of 12 weeks ahead 100% evidence
Exact sum: 24.6 + 15.2 + 16.2 + 4.7 = 60.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -44.2% and the one-year return is -55.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
3Globus Medical, Inc.GMED 58.8/100Mixed-positive evidence81% evidence ASLEEP 25.8/35 Revenue 23.5% · PAT 100% · OPM change 3.6 pp 83% evidence 14.6/25 ROCE 3.2% · OPM 19.8% 76% evidence 14.7/20 P/E 20× · PEG 0.85 65% evidence 3.7/20 RS sector -16.8% · RS bench -14.5% · 1Y 34.6%1 of 12 weeks ahead 100% evidence
Exact sum: 25.8 + 14.6 + 14.7 + 3.7 = 58.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -16.8% and the one-year return is 34.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
4LivaNova PLCLIVN 55.6/100Mixed-positive evidence64% evidence ASLEEP 24.4/35 Revenue 12.4% · PAT — · OPM change 109.8 pp 62% evidence 10.4/25 ROCE 2.3% · OPM 11.4% 76% evidence 9.5/20 P/E 32.6× · PEG — 15% evidence 11.3/20 RS sector 6% · RS bench 9.4% · 1Y 42.7%8 of 12 weeks ahead 100% evidence
Exact sum: 24.4 + 10.4 + 9.5 + 11.3 = 55.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5STERIS plcSTE 53.9/100Mixed-positive evidence81% evidence FADING 21.6/35 Revenue 8.9% · PAT 27.4% · OPM change 5.3 pp 83% evidence 14.5/25 ROCE 3.4% · OPM 19.9% 76% evidence 12.5/20 P/E 27.9× · PEG 1 65% evidence 5.3/20 RS sector -18.7% · RS bench -16.4% · 1Y -15.6%3 of 12 weeks ahead 100% evidence
Exact sum: 21.6 + 14.5 + 12.5 + 5.3 = 53.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Stryker CorporationSYK 53.6/100Mixed-positive evidence85% evidence ASLEEP 23.4/35 Revenue 8.5% · PAT 27.8% · OPM change 6.7 pp 95% evidence 16.4/25 ROCE 4.1% · OPM 25.2% 76% evidence 10.9/20 P/E 32.6× · PEG 1.17 65% evidence 2.9/20 RS sector -24.3% · RS bench -22.1% · 1Y -24.4%4 of 12 weeks ahead 100% evidence
Exact sum: 23.4 + 16.4 + 10.9 + 2.9 = 53.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -24.3% and the one-year return is -24.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
7Integer Holdings CorporationITGR 53.1/100Thin evidence · provisional58% evidence BREAKING OUT 13.3/35 Revenue — · PAT — · OPM change -5.3 pp 45% evidence 10.0/25 ROCE 1% · OPM 7.2% 76% evidence 10.7/20 P/E 21.6× · PEG — 15% evidence 19.1/20 RS sector 25.3% · RS bench 29.4% · 1Y 22.1%9 of 12 weeks ahead 100% evidence
Exact sum: 13.3 + 10 + 10.7 + 19.1 = 53.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8UFP Technologies, Inc.UFPT 52.3/100Mixed-positive evidence81% evidence LEADER 14.9/35 Revenue 11.3% · PAT 7.9% · OPM change -0.4 pp 83% evidence 14.9/25 ROCE 4% · OPM 15.2% 76% evidence 6.8/20 P/E 22× · PEG 2.9 65% evidence 15.7/20 RS sector 9.3% · RS bench 12.4% · 1Y 44.9%12 of 12 weeks ahead 100% evidence
Exact sum: 14.9 + 14.9 + 6.8 + 15.7 = 52.3 · Decision use: Price leads the evidence: RS versus the benchmark is 12.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
9Koninklijke Philips N.V.PHG 51.8/100Mixed-positive evidence75% evidence ASLEEP 23.2/35 Revenue -1.1% · PAT 100% · OPM change 4.8 pp 95% evidence 14.3/25 ROCE 9% · OPM 14% 76% evidence 10.8/20 P/E 20.7× · PEG — 15% evidence 3.5/20 RS sector -18.7% · RS bench -16.2% · 1Y -12%0 of 12 weeks ahead 100% evidence
Exact sum: 23.2 + 14.3 + 10.8 + 3.5 = 51.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.7% and the one-year return is -12%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
10Neogen CorporationNEOG 51.6/100Thin evidence · provisional58% evidence BREAKING OUT 18.0/35 Revenue — · PAT — · OPM change -4 pp 45% evidence 6.7/25 ROCE 0.1% · OPM -1.6% 76% evidence 8.5/20 P/E 1719× · PEG — 15% evidence 18.4/20 RS sector 28% · RS bench 31.7% · 1Y 123.7%8 of 12 weeks ahead 100% evidence
Exact sum: 18 + 6.7 + 8.5 + 18.4 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11Zimmer Biomet Holdings, Inc.ZBH 49.9/100Mixed-negative evidence81% evidence BREAKING OUT 16.0/35 Revenue 9.2% · PAT -16.9% · OPM change 2.6 pp 83% evidence 12.0/25 ROCE 1.9% · OPM 17.9% 76% evidence 12.3/20 P/E 23.5× · PEG 1.09 65% evidence 9.6/20 RS sector -5.1% · RS bench -2.2% · 1Y -3.3%7 of 12 weeks ahead 100% evidence
Exact sum: 16 + 12 + 12.3 + 9.6 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Glaukos CorporationGKOS 49.4/100Thin evidence · provisional55% evidence LEADER 18.8/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence 4.5/25 ROCE -2% · OPM -13.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.1/20 RS sector 21% · RS bench 24.7% · 1Y 95.8%12 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 4.5 + 10 + 16.1 = 49.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Bio-Rad Laboratories, Inc.BIO 48.6/100Mixed-negative evidence64% evidence BREAKING OUT 14.3/35 Revenue 1.9% · PAT — · OPM change 1.8 pp 62% evidence 7.7/25 ROCE 0.4% · OPM 5.8% 76% evidence 9.2/20 P/E 45.9× · PEG — 15% evidence 17.4/20 RS sector 13.2% · RS bench 16.5% · 1Y 33.4%9 of 12 weeks ahead 100% evidence
Exact sum: 14.3 + 7.7 + 9.2 + 17.4 = 48.6 · Decision use: Price leads the evidence: RS versus the benchmark is 16.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
14Insulet CorporationPODD 47.1/100Mixed-negative evidence71% evidence BASING 18.9/35 Revenue 31.9% · PAT -24.6% · OPM change 0.4 pp 83% evidence 14.8/25 ROCE 4.6% · OPM 16% 76% evidence 9.0/20 P/E 48.8× · PEG — 15% evidence 4.4/20 RS sector -43.4% · RS bench -42% · 1Y -57.5%0 of 12 weeks ahead 100% evidence
Exact sum: 18.9 + 14.8 + 9 + 4.4 = 47.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Butterfly Network, Inc.BFLY 46.9/100Thin evidence · provisional55% evidence FADING 19.8/35 Revenue — · PAT — · OPM change 34.7 pp 45% evidence 3.1/25 ROCE -5.5% · OPM -52.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 14.0/20 RS sector 40.2% · RS bench 44.6% · 1Y 292.4%11 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 3.1 + 10 + 14 = 46.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Medtronic plcMDT 46.6/100Mixed-negative evidence85% evidence BREAKING OUT 17.4/35 Revenue 8.4% · PAT 3.1% · OPM change 3 pp 95% evidence 13.7/25 ROCE 2.3% · OPM 19.1% 76% evidence 6.1/20 P/E 22.3× · PEG 3.08 65% evidence 9.4/20 RS sector -7.2% · RS bench -4.7% · 1Y -2.6%7 of 12 weeks ahead 100% evidence
Exact sum: 17.4 + 13.7 + 6.1 + 9.4 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Haemonetics CorporationHAE 46.5/100Mixed-negative evidence81% evidence LEADER 5.0/35 Revenue -2.1% · PAT -41.3% · OPM change -28.2 pp 83% evidence 7.3/25 ROCE -1.2% · OPM -6.6% 76% evidence 14.7/20 P/E 26.4× · PEG 0.52 65% evidence 19.5/20 RS sector 36.7% · RS bench 40.1% · 1Y 110%12 of 12 weeks ahead 100% evidence
Exact sum: 5 + 7.3 + 14.7 + 19.5 = 46.5 · Decision use: Price leads the evidence: RS versus the benchmark is 40.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
18Edwards Lifesciences CorporationEW 45.8/100Mixed-negative evidence85% evidence TURNING 17.3/35 Revenue 14.6% · PAT -30.5% · OPM change 2.7 pp 95% evidence 16.7/25 ROCE 4.2% · OPM 29.5% 76% evidence 3.9/20 P/E 52× · PEG 5.05 65% evidence 7.9/20 RS sector -3.4% · RS bench -0.4% · 1Y 20%3 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 16.7 + 3.9 + 7.9 = 45.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
19Inspire Medical Systems, Inc.INSP 45.8/100Mixed-negative evidence75% evidence BREAKING OUT 17.3/35 Revenue 9.1% · PAT 98.5% · OPM change 0.2 pp 83% evidence 6.5/25 ROCE -0.2% · OPM -0.5% 76% evidence 12.2/20 P/E 11.5× · PEG 1.35 65% evidence 9.8/20 RS sector -2.4% · RS bench -0.6% · 1Y -8.9%7 of 12 weeks ahead 70% evidence
Exact sum: 17.3 + 6.5 + 12.2 + 9.8 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Establishment Labs Holdings Inc.ESTA 44.1/100Mixed-negative evidence61% evidence ASLEEP 25.3/35 Revenue 35.3% · PAT — · OPM change 30.1 pp 62% evidence 4.0/25 ROCE -2.4% · OPM -10.9% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 4.8/20 RS sector -6.5% · RS bench -3.7% · 1Y 80.3%6 of 12 weeks ahead 100% evidence
Exact sum: 25.3 + 4 + 10 + 4.8 = 44.1 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -6.5% and the one-year return is 80.3%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
21NovoCure LimitedNVCR 43.9/100Thin evidence · provisional55% evidence TURNING 16.0/35 Revenue — · PAT — · OPM change -14.3 pp 45% evidence 4.1/25 ROCE -2% · OPM -38.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 13.8/20 RS sector 3.7% · RS bench 7.5% · 1Y 27.8%5 of 12 weeks ahead 100% evidence
Exact sum: 16 + 4.1 + 10 + 13.8 = 43.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22iRhythm Holdings, Inc.IRTC 43.7/100Mixed-negative evidence61% evidence TURNING 23.1/35 Revenue 27.3% · PAT — · OPM change 12.4 pp 62% evidence 5.0/25 ROCE -1.9% · OPM -8.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.6/20 RS sector -28% · RS bench -26.1% · 1Y -36.1%4 of 12 weeks ahead 100% evidence
Exact sum: 23.1 + 5 + 10 + 5.6 = 43.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -28% and the one-year return is -36.1%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
23TransMedics Group, Inc.TMDX 42.2/100Mixed-negative evidence71% evidence BREAKING OUT 16.9/35 Revenue 30.1% · PAT 100% · OPM change -11.5 pp 83% evidence 8.6/25 ROCE 1.3% · OPM 7.6% 76% evidence 10.3/20 P/E 22.6× · PEG — 15% evidence 6.4/20 RS sector -25% · RS bench -23.4% · 1Y -28.4%7 of 12 weeks ahead 100% evidence
Exact sum: 16.9 + 8.6 + 10.3 + 6.4 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Alphatec Holdings, Inc.ATEC 41.1/100Thin evidence · provisional55% evidence BREAKING OUT 23.7/35 Revenue 22.6% · PAT — · OPM change 14.4 pp 62% evidence 3.6/25 ROCE -3.8% · OPM -11.8% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 3.8/20 RS sector -27.5% · RS bench -26.2% · 1Y -32.4%7 of 12 weeks ahead 70% evidence
Exact sum: 23.7 + 3.6 + 10 + 3.8 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
25Axogen, Inc.AXGN 40.7/100Thin evidence · provisional55% evidence FADING 12.3/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence 5.9/25 ROCE -0.9% · OPM -4.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 12.5/20 RS sector 18.5% · RS bench 22.3% · 1Y 164.2%7 of 12 weeks ahead 100% evidence
Exact sum: 12.3 + 5.9 + 10 + 12.5 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26Bruker CorporationBRKR 39.0/100Mixed-negative evidence71% evidence TURNING 7.9/35 Revenue 0.3% · PAT -112.7% · OPM change -2.8 pp 83% evidence 9.3/25 ROCE 0.2% · OPM 1.2% 76% evidence 8.8/20 P/E 79.2× · PEG — 15% evidence 13.0/20 RS sector 18.6% · RS bench 22.1% · 1Y 82.9%9 of 12 weeks ahead 100% evidence
Exact sum: 7.9 + 9.3 + 8.8 + 13 = 39 · Decision use: Price leads the evidence: RS versus the benchmark is 22.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
27GE HealthCare Technologies Inc.GEHC 38.6/100Mixed-negative evidence85% evidence FADING 13.3/35 Revenue 6.5% · PAT -11.5% · OPM change 0.9 pp 95% evidence 13.6/25 ROCE 2.7% · OPM 14% 76% evidence 6.7/20 P/E 14.7× · PEG 3.4 65% evidence 5.0/20 RS sector -20.6% · RS bench -18.5% · 1Y -15.2%5 of 12 weeks ahead 100% evidence
Exact sum: 13.3 + 13.6 + 6.7 + 5 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Abbott LaboratoriesABT 38.2/100Mixed-negative evidence85% evidence BREAKING OUT 6.7/35 Revenue 8.1% · PAT -61.4% · OPM change -5 pp 95% evidence 16.4/25 ROCE 8.8% · OPM 14.7% 76% evidence 6.2/20 P/E 29.3× · PEG 2.89 65% evidence 8.9/20 RS sector -15.5% · RS bench -13.2% · 1Y -24.8%9 of 12 weeks ahead 100% evidence
Exact sum: 6.7 + 16.4 + 6.2 + 8.9 = 38.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
29Penumbra, Inc.PEN 38.2/100Thin evidence · provisional58% evidence ASLEEP 13.9/35 Revenue — · PAT — · OPM change -2.2 pp 45% evidence 10.9/25 ROCE 2.5% · OPM 10.2% 76% evidence 8.6/20 P/E 134.4× · PEG — 15% evidence 4.8/20 RS sector -7.9% · RS bench -5.2% · 1Y 24.6%0 of 12 weeks ahead 100% evidence
Exact sum: 13.9 + 10.9 + 8.6 + 4.8 = 38.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Smith & Nephew plcthis pageSNN 44.5/100Thin evidence · provisional44% evidence ASLEEP 17.6/35 Revenue — · PAT — · OPM change — 16% evidence 12.9/25 ROCE 2.5% · OPM — 61% evidence 11.0/20 P/E 20.4× · PEG — 15% evidence 3.0/20 RS sector -22.3% · RS bench -19.9% · 1Y -24.6%0 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 12.9 + 11 + 3 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Smith & Nephew plc's stock price today?

Smith & Nephew plc trades at $27.8, −24.6% over the past year. The company is valued at $12.0 B. The stock sits at 3% of its 52-week range of $28–$37, −12.7% versus its 200-day average. On the tape, the price is in a downtrend, 4 weeks in. — as of 17 September 2026.

What were Smith & Nephew plc's latest quarterly results?

Smith & Nephew plc reported revenue of $3.1 B and net profit of $0.3 B for the Jun 26 quarter. Revenue rose 4.7% and profit rose 3.4% year on year. Earnings per share were $0.70. The operating margin was 14.5%, 0.0 pp higher than a year earlier. — as of 17 September 2026.

What is Smith & Nephew plc's revenue?

Smith & Nephew plc reported revenue of $3.1 B in the Jun 26 quarter, +4.7% year on year. For the full FY25 fiscal year, revenue was $6.2 B (+6.0%). Over the last 4 years revenue compounded at 4.3% a year. — as of 17 September 2026.

What is Smith & Nephew plc's profit?

Smith & Nephew plc earned $0.3 B of net profit in the Jun 26 quarter, +3.4% year on year — the 6th straight quarter of growth. Full-year FY25 profit was $0.6 B. The operating margin ran 14.5% in the latest quarter. — as of 17 September 2026.

What is Smith & Nephew plc's market cap?

Smith & Nephew plc's market capitalisation is $12.0 B at a stock price of $27.8. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

Does Smith & Nephew plc pay a dividend?

No — Smith & Nephew plc has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.

Is Smith & Nephew plc growing?

Yes — Smith & Nephew plc is growing: latest-quarter revenue +4.7% year on year, profit +3.4%, and the margin +0.0 pp at 14.5%. The 4-year compound rates are 4.3% (revenue) and 4.9% (profit). The earnings engine currently reads: improving — as of 17 September 2026.

How is Smith & Nephew plc performing?

Smith & Nephew plc is in a downtrend, 4 weeks in. Its latest quarter's revenue rose 4.7% and profit rose 3.4% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 22 weeks. This describes what the data did, not a rating. — as of 17 September 2026.

What stage is Smith & Nephew plc in?

Improving — profit growth bottomed 4 quarters ago at −49.5% and has held its recovery at +115.4%, ROCE lifting at 17.7%. The read comes from the last 12 quarters of growth (revenue growth +11.4% latest, profit growth +115.4% latest, eps growth +115.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.

Is Smith & Nephew plc in an uptrend?

No — the price is in a downtrend (week 4 of stage 4), trading −12.7% versus its 200-day average and at 3% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.

Is Smith & Nephew plc beating the market?

Not lately — on a trailing-13-week view Smith & Nephew plc is currently behind the S&P 500 (22 weeks and counting; last ahead the week of 2026-04-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved −19% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.

Will Smith & Nephew plc's stock price go up?

This page publishes no price forecast for Smith & Nephew plc. What it measures instead: the stock price is $27.8, the price is in a downtrend 4 weeks in. Direction is not something this site claims to know. — as of 17 September 2026.

Does Smith & Nephew plc have too much debt?

It is moderate — Smith & Nephew plc's debt-to-equity is 0.73. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.

What is Smith & Nephew plc's capex?

Smith & Nephew plc spent $1.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.4 B. — as of 17 September 2026.

What is Smith & Nephew plc's cash flow?

Smith & Nephew plc generated $1.3 B of operating cash flow in FY25 and $0.8 B of free cash flow after $0.4 B of capital spending. Reported profit that year was $0.6 B, so operating cash ran ahead of profit. — as of 17 September 2026.

Is Smith & Nephew plc's profit real cash?

Yes — over the last 3 fiscal years, 222% of Smith & Nephew plc's reported profit arrived as operating cash. In FY25, operating cash was $1.3 B against reported profit of $0.6 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.

How financially safe is Smith & Nephew plc?

On the balance sheet, the Z-score reads 3.26 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.

Where is Smith & Nephew plc in its business cycle?

Smith & Nephew plc's FY25 operating margin was 12.8%, against a 5-year band of 7.6%–12.8%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 14.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the Smith & Nephew plc story?

The sharpest disagreement: annual EPS moved +52.3% against a −24.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is Smith & Nephew plc a stock worth studying right now?

This is not investment advice. The machine read: Smith & Nephew plc's earnings have outrun its stock. EPS grew +52.3% in a year against a −24.6% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI